Dec 9 (Reuters) - Relmada Therapeutics RLMD.O:
RELMADA THERAPEUTICS TO DISCONTINUE THE RELIANCE II AND RELIGHT PHASE 3 STUDIES OF REL-1017
RELMADA THERAPEUTICS INC: WILL CONTINUE TO ADVANCE PHASE 1 STUDY OF REL-P11, AN INVESTIGATIONAL AGENT FOR TREATMENT OF METABOLIC DISEASE
RELMADA THERAPEUTICS INC: TO EXPLORE STRATEGIC ALTERNATIVES
Source text: ID:nGNX8RxPyd
Further company coverage: RLMD.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.